Vir Biotechnology Inc. (VIR)
NASDAQ: VIRHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
VIR stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.56B
- EPS (TTM)
- -$1.18
- Dividend yield
- None
- 52-week range
- 5.45 – 14.38
- Day range
- 8.34 – 8.92
- Volume / Avg
- 3.09M / 2.45M
- Beta
- —
- Shares outstanding
- 186.27M
52-week range
VIR stock today
On Nov 20, VIR ended the session at $8.39, shedding $0.48 (5.41%), versus the S&P 500's 3.70% decline. Shares are 41.7% below their 52-week high of $14.38, set on Nov 9, 2026 and 53.9% above the 52-week low of $5.45, in the middle of the past year's range. VIR is up 39.1% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 47.7%.
Vir Biotechnology has posted a net loss over the last twelve months (EPS of -$1.18), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Vir Biotechnology
Company profileVir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company's preclinical candidates include those targeting influenza A and B antibodies and antibody drug conjugates, and coronavirus monoclonal antibodies; and PRO-XTEN, a dual-masked TCEs targeting variety of solid tumors.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Marianne De Backer M.B.A., M.Sc., Ph.D.
- Headquarters
- San Francisco, CA
- Employees
- 367
- IPO year
- 2019
- Website
- vir.bio
Financial highlights
Full financialsIn fiscal 2025, Vir Biotechnology generated $68.6 million in revenue, down 7.6% from fiscal 2024, its first annual decline since 2024. Vir Biotechnology reported a net loss of $438.0 million, compared with a loss of $522.0 million a year earlier. Gross margin was 100.0% (up from 98.9%) and operating margin -699.2%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $68.56M | $74.20M | $86.18M | $1.62B | $1.10B |
| Growth | -7.61% | -13.90% | -94.67% | +47.51% | +1334.39% |
| Net income | $-437.99M | $-521.96M | $-615.06M | $515.84M | $528.58M |
| EPS (diluted) | $-3.16 | $-3.83 | $-4.59 | $3.83 | $3.96 |
Analyst forecast
ForecastConsensus (8 analysts)
strong_buy
Avg. price target
$23.38+178.67%
- Strong buy 3
- Buy 5
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 4, 2026
- EPS actual vs est.
- $-0.57 vs $-0.80
- Surprise
- +28.75%
VIR news
All VIR news- Vir Biotechnology, Inc. Prices 15,000,000 Share Public Offering of Common Stock at $10.00 Per ShareNasdaq
- Why is Vir Biotechnology stock tumbling today?Investing.com
- Vir Biotechnology dips 15%, prices $150M equity raise $10 per shareSeeking Alpha
- Vir Biotechnology, Inc. Reports 44% Response Rate in Phase 3 ECLIPSE 1 Trial and Week 96 SOLSTICE DataNasdaq
- Vir Biotechnology shares rise on hepatitis D therapy dataSeeking Alpha
- Vir Biotechnology reports positive hepatitis results, early signs of possible cureSeeking Alpha
- Vir Bio (VIR) Q3 2026 Earnings Call TranscriptNasdaq
- Vir Biotechnology, Inc. Reports Third Quarter 2026 Financial ResultsNasdaq
Vir Biotechnology peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| RXRXRecursion Pharmaceuticals Inc. Class A | 2.45 | -9.93% | $1.53B | vs VIR |
| ALVOAlvotech | 4.12 | -3.96% | $1.47B | vs VIR |
| WWBWindward Bio Group AG | 24.29 | +1.15% | $1.45B | vs VIR |
| MESOMesoblast Limited ADR | 10.89 | -2.59% | $1.41B | vs VIR |
| MAZEMaze Therapeutics Inc. | 31.37 | -3.27% | $1.72B | vs VIR |
| LYCALycia Therapeutics Inc. | 33.07 | +4.09% | $1.72B | vs VIR |
| IMCRImmunocore Holdings plc ADR | 26.41 | -0.83% | $1.36B | vs VIR |
| REPLReplimune Group Inc. | 19.07 | -0.83% | $1.81B | vs VIR |
Indexes, lists and sector
Vir Biotechnology stock FAQ
What is Vir Biotechnology's stock price today?
VIR last traded at $8.39 as of Nov 20, 4:00 PM EST, down 5.41% on the day. Prices are delayed at least 15 minutes.
Who is Vir Biotechnology's CEO?
Dr. Marianne De Backer M.B.A., M.Sc., Ph.D. is the chief executive officer of Vir Biotechnology Inc., which has about 367 employees.
What is the VIR 52-week high?
The 52-week high for VIR is $14.38 and the 52-week low is $5.45. The stock is currently 41.7% below its high.